Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models
- PMID: 15604872
- DOI: 10.1097/01.ico.0000127481.23714.b6
Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models
Abstract
Purpose: To determine the effects of topical cyclosporine A (CsA), an immunomodulating T-cell inhibitor, on the formation of subepithelial immune corneal infiltrates (SEIs) and acute adenovirus replication in the NZW Rabbit Ad5 SEI and Ad5 replication models.
Methods: In the Ad5 SEI model, eyes were treated topically with either 2% CsA in corn oil, 0.5% CsA in artificial tears, or their respective control vehicles 4 times daily for 14 days and then twice daily for 4 days. SEIs were graded on day 23 by masked slit-lamp examination. Using the same treatment protocol in the Ad5 replication model, rabbit eyes were cultured on days 0, 1, 3, 4, 5, 7, 9, 11, 14, 16, 18, and 21 postinoculation, and their tear film viral titers were determined on A549 cells.
Results: The formation of SEIs was significantly reduced following treatment with either 2.0% or 0.5% CsA. However, 2% and 0.5% CsA significantly increased viral titers on several days, prolonged the duration of Ad5 shedding, and increased the number of Ad5-positive cultures per total during the late phase of infection (days 7-21) compared with their respective controls. The 0.5% CsA was equipotent to 2% CsA for most outcome parameters tested.
Conclusions: A role for topical CsA in the treatment of adenovirus ocular infections remains to be defined in large, randomized controlled clinical trials. During acute infection, reducing SEI formation is highly desirable, but enhancing viral replication may inadvertently serve to promote local epidemics. Future trials should address the important issues of optimized formulation and dose regimen and the possibility of prolonging virus shedding.
Similar articles
-
Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.Invest Ophthalmol Vis Sci. 2001 Jan;42(1):158-62. Invest Ophthalmol Vis Sci. 2001. PMID: 11133861
-
Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.Invest Ophthalmol Vis Sci. 2000 Feb;41(2):460-3. Invest Ophthalmol Vis Sci. 2000. PMID: 10670476
-
Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.Invest Ophthalmol Vis Sci. 1997 Jan;38(1):253-7. Invest Ophthalmol Vis Sci. 1997. PMID: 9019458
-
Topical cyclosporine for atopic keratoconjunctivitis.Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009078. doi: 10.1002/14651858.CD009078.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972132 Review.
-
ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.Drugs R D. 2007;8(2):103-12. doi: 10.2165/00126839-200708020-00005. Drugs R D. 2007. PMID: 17324008 Review.
Cited by
-
Ganciclovir ophthalmic gel treatment shortens the recovery time and prevents complications in the adenoviral eye infection.Int Ophthalmol. 2017 Feb;37(1):245-249. doi: 10.1007/s10792-016-0260-1. Epub 2016 May 24. Int Ophthalmol. 2017. PMID: 27221265
-
Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis.Prog Retin Eye Res. 2020 May;76:100826. doi: 10.1016/j.preteyeres.2019.100826. Epub 2019 Dec 28. Prog Retin Eye Res. 2020. PMID: 31891773 Free PMC article. Review.
-
Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.BMC Ophthalmol. 2012 Aug 18;12:42. doi: 10.1186/1471-2415-12-42. BMC Ophthalmol. 2012. PMID: 22900547 Free PMC article. Clinical Trial.
-
[Cyclosporin A eyedrops for keratitis nummularis after adenovirus keratoconjunctivitis].Ophthalmologe. 2008 Jun;105(6):592-4. doi: 10.1007/s00347-008-1731-1. Ophthalmologe. 2008. PMID: 18365204 German.
-
Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions.Clin Ophthalmol. 2020 Mar 17;14:837-852. doi: 10.2147/OPTH.S207976. eCollection 2020. Clin Ophthalmol. 2020. PMID: 32256043 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources